Your browser is no longer supported. Please, upgrade your browser.
Settings
FLDM [NASD]
Fluidigm Corporation
Index- P/E- EPS (ttm)-0.68 Insider Own0.40% Shs Outstand72.49M Perf Week14.74%
Market Cap456.62M Forward P/E- EPS next Y-0.42 Insider Trans-24.13% Shs Float69.36M Perf Month-2.70%
Income-47.70M PEG- EPS next Q-0.07 Inst Own92.80% Short Float9.73% Perf Quarter4.42%
Sales126.00M P/S3.62 EPS this Y34.80% Inst Trans2.47% Short Ratio3.19 Perf Half Y13.41%
Book/sh2.10 P/B3.26 EPS next Y23.60% ROA-16.40% Target Price- Perf Year63.88%
Cash/sh1.08 P/C6.32 EPS next 5Y-8.06% ROE-32.90% 52W Range1.17 - 12.45 Perf YTD14.17%
Dividend- P/FCF- EPS past 5Y12.60% ROI-29.90% 52W High-44.98% Beta1.70
Dividend %- Quick Ratio2.40 Sales past 5Y0.10% Gross Margin59.50% 52W Low485.47% ATR0.48
Employees566 Current Ratio2.90 Sales Q/Q50.60% Oper. Margin-36.80% RSI (14)60.87 Volatility8.39% 6.69%
OptionableYes Debt/Eq0.36 EPS Q/Q55.40% Profit Margin-37.80% Rel Volume5.02 Prev Close6.16
ShortableYes LT Debt/Eq0.36 EarningsFeb 10 AMC Payout- Avg Volume2.12M Price6.85
Recom1.70 SMA2010.86% SMA5010.41% SMA20018.81% Volume9,948,807 Change11.20%
Nov-06-19Downgrade Janney Buy → Neutral
Oct-18-19Upgrade UBS Neutral → Buy $14 → $7
Mar-15-19Initiated UBS Neutral $14
Jan-03-19Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Piper Jaffray Neutral → Overweight
Aug-05-16Reiterated Mizuho Buy $11 → $12
Aug-05-16Reiterated Cantor Fitzgerald Buy $13 → $11
May-05-16Reiterated Mizuho Buy $8 → $11
Apr-12-16Reiterated Leerink Partners Outperform $20 → $15
Jan-07-16Initiated Deutsche Bank Buy $18
Oct-30-15Upgrade Cantor Fitzgerald Hold → Buy $15 → $12
Oct-30-15Reiterated Mizuho Neutral $15 → $8
Aug-27-15Initiated Cantor Fitzgerald Hold
Aug-07-15Reiterated Mizuho Neutral $30 → $15
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
May-08-15Reiterated Maxim Group Buy $52 → $44
May-08-15Downgrade Mizuho Buy → Neutral $50 → $30
May-06-14Reiterated Maxim Group Buy $65 → $52
Apr-23-14Upgrade Mizuho Neutral → Buy $43 → $50
Mar-21-14Reiterated Maxim Group Buy $52 → $65
Jan-22-21 11:45AM  
10:57AM  
10:47AM  
07:22AM  
Jan-21-21 04:05PM  
Jan-07-21 04:02PM  
Jan-05-21 08:30AM  
Dec-25-20 01:41AM  
Dec-15-20 04:05PM  
Dec-08-20 07:15AM  
Nov-27-20 08:34AM  
Nov-24-20 08:30AM  
Nov-23-20 11:00AM  
Nov-22-20 01:00PM  
11:37AM  
Nov-20-20 09:54PM  
01:30PM  
12:40PM  
11:15AM  
10:22AM  
10:00AM  
08:52AM  
Nov-19-20 05:15PM  
04:35PM  
12:28PM  
11:00AM  
10:57AM  
10:54AM  
09:49AM  
09:30AM  
08:30AM  
08:00AM  
06:20AM  
Nov-18-20 09:30PM  
03:20PM  
03:12PM  
01:55PM  
01:42PM  
12:15PM  
11:30AM  
11:00AM  
10:40AM  
10:00AM  
09:42AM  
Nov-17-20 10:27PM  
09:00PM  
05:10PM  
04:23PM  
01:30PM  
01:30PM  
01:00PM  
12:30PM  
11:45AM  
09:58AM  
08:30AM  
Nov-16-20 11:00PM  
10:17PM  
04:15PM  
02:45PM  
12:00PM  
11:15AM  
06:11AM  
Nov-15-20 01:00PM  
Nov-14-20 07:32AM  
Nov-13-20 06:52PM  
04:29PM  
03:02PM  
10:25AM  
09:52AM  
09:05AM  
08:00AM  
Nov-12-20 04:50PM  
03:53PM  
01:04PM  
01:00PM  
11:30AM  
10:50AM  
10:01AM  
Nov-11-20 06:22PM  
04:57PM  
04:25PM  
03:53PM  
01:00PM  
11:56AM  
Nov-10-20 01:55PM  
01:00PM  
12:10PM  
11:30AM  
11:15AM  
10:45AM  
10:26AM  
09:47AM  
08:30AM  
05:59AM  
Nov-09-20 09:31PM  
08:00PM  
04:40PM  
04:15PM  
03:18PM  
03:03PM  
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Linthwaite Stephen ChristopherPresident & CEONov 23Sale6.0684,820514,009145,347Nov 24 05:22 PM
Kreger Bradley AllenSVP, Global OperationsNov 20Option Exercise0.005,362031,778Nov 24 05:22 PM
JOG VIKRAMChief Financial OfficerNov 20Option Exercise0.006,651068,113Nov 24 05:22 PM
Linthwaite Stephen ChristopherPresident & CEONov 20Option Exercise0.0019,4450239,958Nov 24 05:22 PM
McCracken ColinChief Commercial OfficerNov 20Option Exercise0.004,129021,785Nov 24 05:21 PM
Linthwaite Stephen ChristopherPresident & CEOAug 20Option Exercise0.0019,4450230,304Aug 24 07:20 PM
JOG VIKRAMChief Financial OfficerAug 20Option Exercise0.006,650063,762Aug 24 07:19 PM
Kreger Bradley AllenSVP, Global OperationsAug 20Option Exercise0.005,362028,270Aug 24 07:19 PM
McCracken ColinChief Commercial OfficerAug 20Option Exercise0.004,128019,354Aug 24 07:20 PM
Linthwaite Stephen ChristopherPresident & CEOMay 20Option Exercise0.0019,4440216,037May 22 06:29 PM
JOG VIKRAMChief Financial OfficerMay 20Option Exercise0.006,650059,412May 22 06:29 PM
Kreger Bradley AllenSVP, Global OperationsMay 20Option Exercise0.005,361024,762May 22 06:28 PM
McCracken ColinChief Commercial OfficerMay 20Option Exercise0.0016,516022,023May 22 06:29 PM
Paya Carlos VDirectorMar 23Option Exercise0.002,500043,343Mar 25 05:25 PM
BARTHELEMY NICOLASDirectorMar 23Option Exercise0.002,5000151,873Mar 25 05:25 PM
COLELLA SAMUEL DDirectorMar 11Buy2.6510,00026,545161,109Mar 12 09:28 PM
COLELLA SAMUEL DDirectorMar 10Buy2.7710,00027,738151,109Mar 12 09:28 PM
BARTHELEMY NICOLASDirectorMar 06Buy3.0580,000243,872149,373Mar 10 06:59 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERFeb 20Option Exercise0.0013,585058,317Feb 24 07:07 PM
Linthwaite Stephen ChristopherPresident & CEOFeb 20Option Exercise0.0040,0900217,717Feb 24 05:05 PM
Khadder NicholasSee RemarksFeb 20Option Exercise0.0013,159058,022Feb 24 05:06 PM
Kreger Bradley AllenSVP, Global OperationsFeb 20Option Exercise0.0012,071024,336Feb 24 05:05 PM
BARTHELEMY NICOLASDirectorFeb 13Buy3.6412,25744,61469,373Feb 18 08:33 PM